Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism.
Biosynthetic insulin-type growth factor I (IGF-I) was given as an intravenous bolus of 75 micrograms/kg to 9 patients with Laron-type dwarfism. Rapid onset of hypoglycaemia (-45% of basal level) was associated with a reduction in plasma insulin (-55% of basal level); thus, the lack of growth hormone receptors in this condition does not apply to IGF-I receptors and post-receptor pathways. Long-term treatment may therefore be beneficial in Laron-type dwarfism.
D000328:Adult; D002648:Child; D004392:Dwarfism / Q000097:blood / Q000188:drug therapy*; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007328:Insulin / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use*; D008297:Male; D011972:Receptor, Insulin / Q000187:drug effects; D017451:Receptors, Somatomedin; D013002:Somatomedins / Q000627:therapeutic use*
D007328:Insulin; D017451:Receptors, Somatomedin; D013002:Somatomedins; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D011972:Receptor, Insulin